Prestige Consumer Healthcare ( PBH ) Misses Q1 Earnings and Revenue Estimates
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of -5.94% and -4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Prestige ( PBH ) Q1 Revenue Falls 6.6%
Prestige Consumer Healthcare ( NYSE:PBH ) , the over-the-counter ( OTC ) healthcare product company behind brands such as Clear Eyes, Monistat, and Chloraseptic, released its first-quarter results for fiscal 2026 on August 7, 2025.
Stay Ahead of the Game With Prestige Consumer Healthcare ( PBH ) Q1 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top-and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
AdaptHealth Corp. ( AHCO ) Lags Q2 Earnings and Revenue Estimates
AdaptHealth (AHCO) delivered earnings and revenue surprises of -93.33% and -0.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Dolores Catania Teams Up with Advanced Herbals®, from the Makers of Dramamine®, to Launch The Dish on GLP-1s Content Series and Tackle One of the Most Common Complaints from GLP-1 Users: Nausea
Advanced Herbals® and the reality TV star are sharing new, original content aimed to help the majority ( 64% ) of GLP-1 users who wish they had more education about the medications' side effects TARRYTOWN, N.Y., July 15, 2025 /PRNewswire/ -- Side effects can crash the GLP-1 party - and most ...
Prestige Consumer Healthcare to Release Fiscal 2026 First Quarter Earnings Results
TARRYTOWN, N.Y., July 15, 2025 ( GLOBE NEWSWIRE ) -- Prestige Consumer Healthcare Inc. ( NYSE:PBH ) today announced that it will issue its fiscal 2026 first quarter earnings release on Thursday, August 7, 2025 before the opening of the market.
Medtech Products Inc. Issues Nationwide Recall of Little Remedies® Honey Cough Syrup Due to Microbial Contamination - Prestige Consumer ( NYSE:PBH )
TARRYTOWN, N.Y., June 17, 2025 ( GLOBE NEWSWIRE ) -- Medtech Products Inc., a Prestige Consumer Healthcare Inc. company ( "Medtech" or "Company" ) , is voluntarily recalling five lots of Little Remedies® Honey Cough Syrup ( the "Product" ) due to the presence of Bacillus cereus and loss of ...
Medtech Products Inc. Issues Nationwide Recall of Little Remedies® Honey Cough Syrup Due to Microbial Contamination
TARRYTOWN, N.Y., June 17, 2025 ( GLOBE NEWSWIRE ) -- Medtech Products Inc., a Prestige Consumer Healthcare Inc. company ( "Medtech" or "Company" ) , is voluntarily recalling five lots of Little Remedies® Honey Cough Syrup ( the "Product" ) due to the presence of Bacillus cereus and loss of ...
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition
TMO grapples with macro pressures, rising expenses and fierce competition, but bets on acquisitions to fuel recovery.
Here's Why You Should Retain AMED Stock in Your Portfolio for Now
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Here's Why You Should Retain PODD Stock in Your Portfolio Now
Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.
Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference - Prestige Consumer ( NYSE:PBH )
TARRYTOWN, N.Y., June 09, 2025 ( GLOBE NEWSWIRE ) -- Prestige Consumer Healthcare Inc. PBH today announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference virtually on Wednesday, June 11, 2025 at 10:30 a.m.
Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference
TARRYTOWN, N.Y., June 09, 2025 ( GLOBE NEWSWIRE ) -- Prestige Consumer Healthcare Inc. ( NYSE:PBH ) today announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference virtually on Wednesday, June 11, 2025 at 10:30 a.m.
PEN Stock Rises Following the Launch of Ruby XL System
Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
OMCL stays on investors' radar due to its strong 2025 growth targets with automation and tech services, but faces margin risks from macro and competitive headwinds.
TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?
Thermo Fisher debuts two advanced MSs, Orbitrap Astral Zoom and Orbitrap Excedion Pro, to accelerate precision medicine and drug discovery breakthroughs.
Here's Why You Should Retain ICLR Stock in Your Portfolio Now
Investors remain optimistic about ICON, driven by its commitment to enhance clinical delivery by integrating AI and impressive strategic pacts.
LH Stock Rises Following the Expansion of Precision Oncology Portfolio
Labcorp expands its precision oncology lineup with new cancer tests and a global diagnostic tool.
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare ( PBH Quick QuotePBH - ) and Stryker ( SYK Quick QuoteSYK - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds
ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.
Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?
TMO unveils spectral-enabled Attune Xenith Flow Cytometer to streamline workflows and boost research accuracy.
Bruker Stock to Gain From the Launch of MOVE-T Liquid Dairy Analyzer
BRKR unveils the MOVE-T analyzer to boost quality and efficiency in the dairy industry, setting new standards for precision and reliability.
Is Bio-Techne Stock the Right Pick for Your Portfolio Now?
TECH is gaining ground in cell and gene therapy, and with Ella, while navigating macro hurdles. Is it the right fit for your portfolio today?
The Sandlot Star Patrick Renna Teams Up with Dramamine® to Revisit an Iconic Scene - This Time, Puke Free
The Advanced Herbals™ supplement line by the makers of Dramamine® is giving Americans the chance to win a vacation do-over, this time with Ginger Chews as a solution for unwelcome nausea
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.
TMO Stock Set to Gain From the Launch of New Narcotic Analyzers
Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.
Insulet Gains 78.5% in a Year: What's Driving the Stock?
PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds.
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
Investors are optimistic about HSIC, owing to the strong performance of its Henry Schein One business.
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Penumbra Rallies 35.9% in a Year: What's Driving the Stock?
PEN has shown notable strength over the past year, driven by the performance of its core U.S. thrombectomy business. Solid international prospects instill optimism.
Should Tandem Diabetes Stock Stay in Your Portfolio Now?
Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.
AST Business Growth & Strategic Acquisitions Support STERIS Stock
STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?
DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
Should You Continue to Hold Charles River Stock in Your Portfolio?
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
PBH vs. ESLOY: Which Stock Should Value Investors Buy Now?
PBH vs. ESLOY: Which Stock Is the Better Value Option?
Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase
PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.
Prestige Consumer Healthcare ( PBH ) Tops Q4 Earnings and Revenue Estimates
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 1.54% and 2.62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
TARRYTOWN, N.Y., May 08, 2025 ( GLOBE NEWSWIRE ) -- Prestige Consumer Healthcare Inc. ( NYSE:PBH ) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025.
Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
TARRYTOWN, N.Y., May 08, 2025 ( GLOBE NEWSWIRE ) -- Prestige Consumer Healthcare Inc. ( NYSE:PBH ) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025.
Insights Into Prestige Consumer Healthcare ( PBH ) Q4: Wall Street Projections for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Prestige Consumer Healthcare ( PBH ) Reports Next Week: Wall Street Expects Earnings Growth
Prestige Consumer Healthcare (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GE HealthCare Technologies ( GEHC ) Q1 Earnings and Revenues Top Estimates
GE HealthCare (GEHC) delivered earnings and revenue surprises of 10.99% and 2.57%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
EMEA Growth & Product Launches to Support Boston Scientific Stock
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
PBH or ABT: Which Is the Better Value Stock Right Now?
PBH vs. ABT: Which Stock Is the Better Value Option?
Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results - Prestige Consumer ( NYSE:PBH )
TARRYTOWN, N.Y., April 10, 2025 ( GLOBE NEWSWIRE ) -- Prestige Consumer Healthcare Inc. PBH today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market.
Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results
TARRYTOWN, N.Y., April 10, 2025 ( GLOBE NEWSWIRE ) -- Prestige Consumer Healthcare Inc. ( NYSE:PBH ) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market.
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare ( PBH Quick QuotePBH - ) and Stryker ( SYK Quick QuoteSYK - ) . But which of these two stocks presents investors with the better value opportunity right now?
PBH or BSX: Which Is the Better Value Stock Right Now?
PBH vs. BSX: Which Stock Is the Better Value Option?
